transMedChem was established 2012 by Dr. Peter Sennhenn, a passionate medicinal chemist, drug hunter and entrepreneur with 30 years of industry experience and expertise in various therapeutic areas and target families.
transMedChem provides drug discovery advisory and operational execution of small molecule optimization programs along the whole R&D pipeline in an accelerated and cost-efficient manner employing state-of-the art software tools and integrated AI.
We specialize in translating and advancing novel protein targets and mode-of-actions (MOA) from basic reasearch into clinical drugs, offering guidance along the entire preclinical R&D pipeline
transMedChem offers taylormade solutions based on flexible business models, specifically designed for academic institutions, startups, and biotech companies to translate and advance innovative targets and ideas into commercial pharmaceutical products complying with industry standards.
transMedChem strives to sustainably close the innovation gap between basic research and the pharmaceutical industry by translating basic biomedical science into novel medicines.
transMedChem exploits a broad and well-established expert network that can be accessed to master challenges and identify the most efficient, cost- and time-saving approach to advance your discovery program.
